Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors  by Zoccali, Carmine et al.
Kidney International, Vol. 63, Supplement 84 (2003), pp. S98–S102
Adiponectin is markedly increased in patients with nephrotic
syndrome and is related to metabolic risk factors
CARMINE ZOCCALI, FRANCESCA MALLAMACI, VINCENZO PANUCCIO, GIOVANNI TRIPEPI,
SEBASTIANO CUTRUPI, SAVERIO PARLONGO†, FRANCESCO CATALANO, SACHIYO TANAKA,
NORIYUKI OUCHI, SHINJI KIHARA, TOHRU FUNAHASHI, and YUJI MATSUZAWA
Laboratorio di Epidemiologia, Clinica e Fisiopatologia delle Malattie, Renali, e dell’Ipertensione Arteriosa, Istituto di Biomedicina,
Reggio Calabria, Italy; and Department of Internal Medicine & Molecular Science, Osaka University, Osaka, Japan
Adiponectin is markedly increased in patients with nephrotic series of proteins spanning from TNF- and angiotensin-
syndrome and is related to metabolic risk factors. ogen to plasminogen activator inhibitor type-1 and leptin.
Background. Adiponectin (ADPN), the gene product of These proteins impinge upon important body functionsapM1, is the most abundant secretory protein of the adipose
ranging from inflammation, hematopoiesis, and immu-tissue in human plasma. Altered regulation (reduced synthesis)
nomodulation, to sympathetic activity [1]. Of particularof this substance may be relevant to endothelial dysfunction
and cardiovascular complications in patients with ESRD. interest is the emerging hypothesis that disordered endo-
Methods. We investigated the relationship between plasma crine function of the adipocyte may contribute to cardio-
ADPN, glomerular filtration rate (GFR) (plasma iohexol clear- vascular disease [2], a concept supported by the observa-ance), and metabolic risk factors in 16 patients with nephrotic
tion that high fat mass is associated to raised plasmasyndrome, in 25 patients with chronic nephropathies without
concentration of vasculotoxic cytokines, such as TNF,nephrotic syndrome, and in 31 healthy subjects.
Results. Plasma ADPN was much higher (P  0.01) in pa- and to high circulating levels of leptin, which is a recog-
tients with nephrotic syndrome (24.4  14.9 g/mL) than in nized sympathetic trigger and a predictor of cardiovascu-
patients with chronic nephropathies without nephrotic syndrome lar events [3]. Adiponectin (ADPN) is the most abundant(12.3  7.2 g/mL) and healthy subjects (5.9  2.6 g/mL). In
adipose tissue protein in human plasma [4]. ADPN is athe aggregate 24-hour, proteinuria (r  0.53, P  0.01) and
particularly interesting compound because it may haveserum cholesterol (r  0.53, P  0.01) were strong and direct
correlates of plasma ADPN, while serum albumin correlated a protective influence on the cardiovascular system. In-
inversely (r  0.46, P  0.01) with this protein. Proteinuria deed, it suppresses the attachment of monocytes to endo-
appeared to be an important confounder of the relationship
thelial cells and modulates the endothelial response tobetween ADPN and the GFR because in the whole patient
inflammatory stimuli [5] The potential protective rolepopulation (with and without nephrotic syndrome), this rela-
tionship emerged only after data adjustment for 24-hour pro- of adiponectin in human diseases is supported by the
teinuria (partial r0.31, P 0.05), while no such relationship observation that plasma ADPN is low in patients with
was demonstrable on crude data analysis (r  0.03, P  0.87). coronary artery disease [5] and in patients with type 2
Conclusions. ADPN is markedly increased in patients with
diabetes mellitus [6].nephrotic syndrome, and proteinuria is strongly related to cir-
Renal insufficiency is a notorious trigger of cardiovas-culating ADPN in patients with nephrotic and non-nephrotic
renal diseases. The relationships between plasma ADPN, se- cular complications because, in this condition, endothe-
rum cholesterol, and serum albumin suggest that this adipocyte lial dysfunction and atherosclerosis are almost universal.
protein may serve to mitigate endothelial damage triggered by Preliminary observations in our laboratory indicated thatdyslipidemia and other risk factors in patients with chronic
ADPN is inversely related to creatinine clearance [7];renal diseases.
this finding has been recently confirmed in a large survey
in patients with dyslipidemia [8]. Furthermore, we have
also shown that ADPN is markedly increased in patientsIn the last decade substantial evidence has been ac-
with ESRD [9]. However, it is unknown whether thecrued showing that the adipose tissue produces a large
increase in plasma ADPN observed in patients with renal
diseases depends purely on accumulation of this protein
†Deceased. or represents a counter-regulatory response to the sev-
eral metabolic and hemodynamic risk factors of renalKey words: adipose tissue, adiponectin, nephrotic syndrome, cytokines,
IL-6, TNF-, cardiovascular risk, nutrition, ESRD, uremia, dialysis. insufficiency. Nephrotic syndrome is a high-risk situation
because, also independent of renal function, unabated 2003 by the International Society of Nephrology
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Table 1. Clinical and biochemical data of the three study groups
Patients with Patients without
nephrotic syndrome nephrotic syndrome Healthy subjects
(N  16) (N  25) (N  31)
Age years 4915 5017 478
Males N % 13 (81%) 14 (56%) 16 (52%)
BMI kg/m2 24.64.2a 24.64.8a 27.03.0
Systolic pressure mm Hg 13624a 13616a 11413
Diastolic pressure mm Hg 8616a 8015a 728
Plasma adiponectin lg/mL 24.414.9a,b 12.37.2a 5.92.6
Serum albumin g/dL 2.30.4b 3.60.6
Serum cholesterol mg/dL 293115a,b 16746 16734
Serum tryglicerides mg/dL 255144a,b 13774a 9750
Serum glucose mg/dL 8019b 8920 937
GFR Iohexol clearance mL/min/1.73 m2 7416a,b 4127
Proteinuria g/24 hours 6.82.6b 0.981.30
On antihypertensive treatment N % 13 (81%) 17 (68%)
Data are meanSD or percent frequency, as appropriate.
aP  0.01 vs. healthy subjects
bP  0.01 vs. patients without nephrotic syndrome
urinary protein loss triggers hypoalbuminemia, hyperfi- beta blockers, or diuretics, and the remaining 11 were
on double, triple, or quadruple therapy with various com-brinogenemia, and hypercholesterolemia. Therefore, in
binations of these drugs. Furthermore, six patients withthis study we have specifically investigated the relation-
nephrotic syndrome were on treatment with prednisoneship between adiponectin and cardiovascular risk factors
(12.5 to 75 mg/day). The control group was made upin a series of patients with nephrotic syndrome. We then
of thirty-one healthy, normotensive subjects who werecompared this series to a group of patients with non-
accurately matched to patients for age and sex. Serumnephrotic kidney diseases and to a group of normoten-
creatinine in healthy subjects was 0.87  0.15 mg/dL.sive healthy subjects.
All subjects that took part in this study were of Caucasian
descent.
METHODS
Study protocolThe protocol was in conformity with the ethical guide-
lines of our institution and informed consent was ob- Studies were performed between 8 am and 10 am fol-
tained from each participant. lowing a 12-hour overnight fast. Smoking and coffee
were forbidden for at least 12 hours before sampling.
Patients On the day of the study, each subject was seated in an
We studied 41 patients, (27 M, 14 F) with various armchair in a well-lighted room and an intravenous can-
degrees of renal dysfunction, from normal to severely nula was introduced into a peripheral vein. Arterial pres-
impaired (serum creatinine range, 0.50 mg/dL to 12.3 sure was measured three times (Dinamap 1846 with auto-
mg/dL). The main demographic, somatometric, clinical, matic recorder [Dinamap, Criticon, Tampa, Florida])
and biochemical data of these patients are reported in after a 10-minute resting period, and then blood sampling
Table 1. The causes of chronic renal disease were: mem- was performed without venostasis for measurements of
branous nephropathy in nine cases; IgA nephropathy plasma adiponectin, serum creatinine, serum cholesterol,
in five patients; pyelonephritis in three patients; focal serum tryglicerides, and serum glucose.
glomerular sclerosis in two patients; amyloidosis in two
Laboratory methodspatients, renal artery stenosis in one patient; vasculitis
in one patient, diabetes in one patient; nephroangio- The concentration of plasma ADPN was measured by
slerosis in one patient; mesangio-proliferative nephropa- a sensitive ELISA [10] in the Laboratory of the Depart-
thy in one patient, lupus nephritis in one patient; obstruc- ment of Internal Medicine and Molecular Science of
tive nephropathy in one patient; minimal change was the Medical School of Osaka, Japan. The glomerular
found in two patients; and the remaining 11 cases were filtration rate (GFR) was estimated by the measurement
undefined. Sixteen patients had full-blown nephrotic syn- of iohexol clearance [11].
drome. Thirty patients were on anti-hypertensive treat-
Statistical analysisment (Table 1) with various drugs. Nineteen were on
monotherapy with ACE inhibitors or angiotensin II re- Data were reported as mean  SD or as percent fre-
quency, and comparisons between groups were made byceptor antagonists, calcium antagonists, sympathicolitics,
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Fig. 1. Relationship between plasma ADPN
(expressed as lg10) and 24-hour proteinuria,
serum cholesterol, and serum albumin in 41
patients with chronic renal diseases. Data are
shown as Pearson product moment correla-
tion coefficients and P values.
t test, Mann-Whitney test, or chi-square test, as appro- changed (both P still 0.01) after data adjustment for
priate. Variables that did not show a Gaussian distribu- BMI. The proportion of patients on anti-hypertensive treat-
tion were log transformed before further analyses (lg10). ment was similar in patients with and without nephrotic
Relationships between paired parameters were analyzed syndrome (Table 1), although a larger fraction of ne-
by the least squares method. phrotic patients were on diuretics (31% vs. 16%, P 
The independent association between plasma ADPN NS). Likewise, steroid treatment did not appear to mod-
and GFR and other variables was tested by reduced ify plasma ADPN because the plasma concentration of
multiple regression models (i.e., models including, at this substance was higher in the 11 patients with nephrotic
most, two predictor covariates at a time). Data were syndrome who were off steroids (26.0 18.3 g/mL) than
expressed as partial correlation coefficient and P value. in the remaining five nephrotic patients on prednisone
All calculations were done using a standard statistical treatment (23.8  14.0 g/mL).
package (SPSS for Windows, version 9.0.1, Chicago, IL,
USA). Functional correlates of plasma adiponectin
In the aggregate 24 hour, proteinuria and serum cho-
lesterol were strong and direct correlates of plasma adi-RESULTS
ponectin, while serum albumin correlated inversely withAs shown in Table 1, the two groups of patients with
this protein (Fig. 1). Interestingly, the association be-chronic nephropathies were well matched to healthy sub-
tween plasma adiponectin and these covariates becamejects for age and sex, but exhibited lower BMI and higher
even stronger after data adjustment for BMI and sexarterial pressure. As expected, patients with nephrotic
(adiponectin-proteinuria: partial r  0.65, P  0.001;syndrome had substantially higher plasma concentra-
adiponectin-cholesterol: partial r  0.65, P  0.001; adi-tions of serum cholesterol and triglycerides and lower
ponectin-serum albumin: partial r  0.52, P  0.002).serum albumin levels than patients without nephrotic
Separate analysis of patients with and without nephroticsyndrome.
syndrome showed that in the latter group, plasma adipo-Plasma adiponectin was substantially higher (P 0.01)
nectin was significantly and inversely related to GFR (rin patients with nephrotic syndrome than in those with-
0.46, P  0.02) and such a relationship remained un-out nephrotic syndrome and in healthy subjects (Table 1).
modified after introducing BMI as a second covariateThe between groups differences in plasma ADPN were
largely independent of BMI because they remained un- into the linear model (partial r  0.44, P  0.046). In
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contrast, no such relationship emerged in patients with The strong relationship between this protein and insulin
sensitivity suggests that there must be an important crossnephrotic syndrome (r  0.09, P  0.72). Proteinuria
appeared to be an important confounder of the relation- talk between fat cells, neurohormonal factors, and the
main insulin target organs, such as the liver. Thus, itship between adiponectin and the GFR because in the
whole patient population (with and without nephrotic can be speculated that albumin and protein depletion
in nephrotic syndrome, besides triggering the profoundsyndrome), this relationship emerged only after data ad-
justment for proteinuria (partial r  0.31, P  0.05), metabolic changes leading to hyperlipidemia and hyper-
fibrinogenemia in the liver, also trigger a parallel increasewhile no such relationship was demonstrable on crude
data analysis (r  0.03, P  0.87). in adiponectin synthesis in fat cells. Increasing adiponec-
tin (i.e., an anti-inflammatory protein) would indeed be
an appropriate adaptation to limit the deleterious effects
DISCUSSION
of acute-phase reaction set in motion in this syndrome.
In patients with full-blown nephrotic syndrome, adipo- Notably, we found that plasma adiponectin was twice as
nectin is markedly raised and strongly associated with high in nephrotic patients as in patients without ne-
typical biochemical features of this syndrome (i.e., hyper- phrotic syndrome, even though the GFR was lower in
cholesterolemia and hypoalbuminemia). These data sug- this latter group. Thus, the (unknown) stimulus-rising
gest that hyperadiponectinemia in nephrotic syndrome plasma adiponectin must be of relevance because it
is a counter-regulatory response aimed at attenuating the seems to override the effect of the GFR.
vasculotoxic effect of the biochemical alterations which Apart from chronic renal failure, nephrotic syndrome
attend this syndrome. is the only disease associated with raised plasma ADPN,
Adiponectin is a collagen-like protein of the collectin and therefore it also represents a useful model to under-
family, which is synthesized exclusively in the adipose stand the pathophysiologic implications of this sub-
tissue. This adipocyte protein binds to the major collagen stance. In this regard, it is important to emphasize that
components of the vascular intima (collagens I, III, and the direction of the relationship between adiponectin
V) and accumulates in the vascular wall when the endo- and metabolic risk factors like cholesterol and albumin
thelial barrier is damaged [12]. Plasma adiponectin has in nephrotic patients is just the opposite to that found
been measured in apparently healthy PIMA Indians and in other diseases such as obesity and diabetes. In obesity
Caucasians [13], in high-risk patients with ischemic heart and in type 2 diabetes (i.e., two conditions linked to
disease [5], in obese patients [10], in young hypertensive insulin resistance and to positive energy balance), low
men [14], in type 2 diabetics [6], and in patients with adiponectin seems to be an initiating event in the patho-
ESRD [9]. Interestingly, in all of these studies, low genesis of insulin resistance [19]. It may be that, in sec-
plasma adiponectin was coherently associated to markers ondary forms of insulin resistance and hyperlipidemia,
of high cardiovascular risk. Thus, it was lower in patients such as in nephrotic syndrome [20], in which the energy
who had suffered myocardial infarction [5] and in diabet- balance is often negative, stimuli amplifying the synthesis
ics [6], while in obese patients [10] and in apparently of adiponectin prevail on suppressive factors, thus lead-
healthy Pima Indians and Caucasians [13], low adiponec- ing to an appropriate, marked increase in the plasma
tin was strongly related to insulin resistance. Of note, concentration of this protein. Serial observations and
ADPN in patients with ESRD is substantially increased experimental studies in animal models are required to
in comparison to healthy subjects, but within the uremic clarify factors responsible for hyperadiponectinemia in
population, low adiponectin is still a marker of high risk nephrotic syndrome. Understanding these factors will
because it predicts a relatively higher rate of incident probably have implications for other disease states, ex-
cardiovascular events [9]. tending well beyond nephrotic syndrome.
Patients with nephrotic syndrome have a high risk of
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